NCT05840952View on ClinicalTrials.gov

A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 4, 2023

Primary Completion Date

April 29, 2024

Study Completion Date

April 29, 2024

Conditions
COVID-19
Interventions
DRUG

ALG-097558

single or multiple doses of ALG-097558

DRUG

Placebo

single or multiple doses of placebo

DRUG

Midazolam

Multiple doses of Midazolam

DRUG

Itraconazole

Multiple doses of Itraconazole

DRUG

Carbamazepine

Multiple doses of Carbamazepine

DRUG

ALG-097558 in solution formulation

ALG-097558 in solution administered in fasted state

DRUG

ALG-097558 in tablet formulation

ALG-097558 in tablet administered in fasted and fed state

Trial Locations (1)

Unknown

Hammersmith Medicines Research, London

Sponsors
All Listed Sponsors
lead

Aligos Therapeutics

INDUSTRY

NCT05840952 - A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558 | Biotech Hunter | Biotech Hunter